Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study

Abstract Aims To describe the characteristics of patients receiving evolocumab in clinical practice across 12 European countries and simulate the association between low-density lipoprotein cholesterol (LDL-C) reduction and cardiovascular (CV) risk reduction. Methods and results The characteristics...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European heart journal. Quality of care & clinical outcomes 2022-06, Vol.8 (4), p.447-460
Hauptverfasser:	Ray, Kausik K, Dhalwani, Nafeesa, Sibartie, Mahendra, Bridges, Ian, Ebenbichler, Christoph, Perrone-Filardi, Pasquale, Villa, Guillermo, Vogt, Anja, Bruckert, Eric
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiovascular disease Cholesterol Disease prevention High density lipoprotein Life Sciences Low density lipoprotein Monoclonal antibodies Original Statins
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!